Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07719946 | To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers | recruiting | Phase 2 | 20 | Tata Memorial CentreOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT02251548 | A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia(iFCR) | active not recruiting | Phase 2 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 21, 2026 |
| NCT04409639 | Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations(CONCERTO) | active not recruiting | Phase 2 | 14 | University of UtahOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03190915 | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | active not recruiting | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03739502 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant(HBO-UBC) | active not recruiting | Phase 2 | 64 | University of RochesterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | active not recruiting | Phase 2 | 155 | Daiichi SankyoINDUSTRY | 12 | Jul 20, 2026 | clinicaltrials |
| NCT05821088 | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | active not recruiting | Phase 2 | 37 | David Bond, MDOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06026371 | Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation | active not recruiting | Phase 2 | 157 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06649695 | A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis | active not recruiting | Phase 2 | 30 | European Myeloma Network B.V.NETWORK | 6 | Jul 20, 2026 | clinicaltrials |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | recruiting | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | not yet recruiting | Phase 2 | 105 | Kure Cells, INCINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR(BIG-1) | recruiting | Phase 2 / Phase 3 | 3,100 | University Hospital, AngersOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04439318 | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | active not recruiting | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04439357 | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04783415 | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 12 | City of Hope Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05690984 | Elimination of Minimal Residual Disease After Transplant(EMAT) | active not recruiting | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06385483 | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) | active not recruiting | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06390826 | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) | active not recruiting | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06390839 | Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) | active not recruiting | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06461988 | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | recruiting | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06810778 | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis(ALANIS) | recruiting | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT07392242 | A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma(GLORY) | not yet recruiting | Phase 2 | 56 | Massachusetts General HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01352520 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | active not recruiting | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01515527 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03282396 | Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03610438 | Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia(ALL2418) | active not recruiting | Phase 2 | 76 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03817398 | Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 110 | Children's Oncology GroupNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03896737 | Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara | active not recruiting | Phase 2 | 401 | European Myeloma Network B.V.NETWORK | 3 | Jul 16, 2026 | clinicaltrials |
| NCT04022239 | Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04231851 | CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | active not recruiting | Phase 2 | 30 | University of California, IrvineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04564703 | Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients | active not recruiting | Phase 2 | 160 | Stichting European Myeloma NetworkNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT04712539 | Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05469893 | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | recruiting | Phase 2 | 52 | Irene Ghobrial, MDOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05929612 | A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06533748 | Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | recruiting | Phase 2 | 128 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708987 | Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.(Withaferin_A) | recruiting | Phase 2 | 34 | Tata Memorial CentreOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709013 | Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients | recruiting | Phase 2 | 22 | Tata Memorial CentreOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients(STOMP) | recruiting | Phase 1 / Phase 2 | 300 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 22, 2026source: clinicaltrials